Dabigatran

The safety and efficacy of Pradaxa (dabigatran) were evaluated in the European RE-ALIGN trial... use of specific reversal agents such as idarucizumab for dabigatran, and emergency...

Praxbind® (idarucizumab) | Pradaxa® Reversal Agent

Product information on treatment with PRAXBIND, the ONLY FDA-approved specific reversal agent for a NOAC available in all 50 states. Adverse reactions may occur with PRAXBIND. View Important Safety Information and Full Prescribing Information on website.

When will NOAC reversal agents be available in Korea? < Pharma < Article

Several drugs that reverse the blood thinning effect of non-vitamin K oral anticoagulants (NOAC) have arrived in the global market, but it will take some time for Korean physicians to use them, experts said. Representative NOAC reversal agents are used against Pradaxa (ingredient: dabigatran), Eliquis (apixaban), and Xarelto (rivaroxaban). The NOAC market has expanded rapidly as NOACs lowered the bleeding risk in stroke prevention treatment for atrial fibrillation patients, compared to warfarin....

Idarucizumab administration in emergency situations: the Munich Registry of Reve - 전자자원 상세

Idarucizumab administration in emergency situations: the Munich Registry of Reversal of Pradaxa[R] in clinical routine (MR REPAIR)

Pradaxa (dabigatran): Uses, side effects, dosage, and more

Pradaxa (dabigatran) is a brand-name drug used to decrease your risk of developing a blood clot. Learn about side effects, dosage, reversal of bleeds, and more.

Pradaxa® (dabigatran etexilate) for Healthcare Professionals

WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF...

Dosing and Administration of Pradaxa® (dabigatran etexilate)

WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF...

[논문]Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran

Objective:To evaluate the role of idarucizumab, a humanized monoclonal antibody fragment, as a specific reversal agent for the anticoagulant activity of dabigatran and to review the pharmacology, p...

Pradaxa (dabigatran) dosing, indications, interactions, adverse effects, and more

Prevention of stroke and systemic embolism associated with... not recommendedIndicated for treatment of deep vein thrombosis... risk of recurrence of DVT and PE in patients who have been...

PRADAXA® (dabigatran etexilate) capsules, for oral use Initial U.S. Approval: 20

Approval: 2010 WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS, and (B) SPINAL/EPIDURAL HEMATOMA See full prescribing information for complete...